MRK's ATLAS-UC Data & SYRE's SKYLINE-UC Bring Validation & Stock Movement

Research evidence excerpt

MRK's ATLAS-UC Data & SYRE's SKYLINE-UC Bring Validation & Stock Movement

tion of participants achieving clinical

remission has primary completion listed as May 9, 2028 (per clinicaltrials.gov) — Recruiting

• SNY/TEVA's duvakitug 40-week Ph3 SUNSCAPE-2 (NCT07185009) in n=671 moderately-to-

severely active UC patients with primary endpoint proportion who achieve clinical remission

by modified Mayo Score (mMS) in the pivotal maintenance sub-study Cohort 1 has primary

completion listed as September 21, 2028 (per clinicaltrials.gov) — Recruiting

• SYRE's (not covered) SPY002 96-week Ph2 SKYLINE-LTE (NCT07652294) in n=645

moderate-to-severe active UC patients with primary endpoint of TEAEs has primary

completion listed as March 2, 2029 (per clinicaltrials.gov) — Enrolling by invitation

• SNY/TEVA's duvakitug 12-week Ph3 STARSCAPE-1 (NCT07184931) in n=980 moderately-

to-severely active Crohn's disease patients with sub-study 2 co-primary endpoints for the US/

FDA of proportion of patients achieving clinical remission per CDAI and endoscopic response

per SES-CD, and co-primary endpoints for the EU/EMA of proportion of patients who achieve

clinical remission per PRO-2 and endoscopic response per SES-CD has primary completion

listed as May 14, 2029 (per clincialtrials.gov) — Recruiting

• SNY/TEVA's duvakitug 40-week Ph3 STARSCAPE-2 (NCT07184944) in n=751 moderately-

to-severely active Crohn's disease patients with co-primary endpoints for the US/FDA of

proportion of patients achieving clinical remission per CDAI and endoscopic response per

SES-CD, and co-primary endpoints for the EU/EMA of proportion of patients who achieve

listed as August 13, 2029 (per clinicaltrials.gov) — Recruiting

Shattuck Labs, Inc. Page 3 of 8